On November 14th, 2020, Bo'ao Winhealth Rare Disease Medical Center was 
officially launched, jointly built by Hainan Bo'ao International Medical 
Tourism Pilot Zone Administration, Winhealth Pharma Group (HK) and Bo'ao 
Worldlight Hospital.

Main leaders of Hainan Provincial Health Commission, Hainan Medical Products 
Administration, Hainan Bo'ao International Medical Tourism Pilot Zone 
Administration, Winhealth Pharma Group (HK), Bo'ao worldlight hospital, etc 
attended the ceremony and delivered speeches. Authoritative experts on rare 
diseases from major Chinese provinces and cities, representatives from China 
biggest patient groups like ICF and CORD and representatives from 
multi-national pharmaceutical companies attended as well. Besides, Winhealth 
and Ethypharm completed the signing ceremony of orphan drug Orphacol®.

Since acquiring the authorization from Lecheng Administration, the center has 
established cooperation with various experts and institutes for rare diseases, 
patient groups and various domestic and oversea pharmaceutical companies. With 
the mission of "To become the most comprehensive and advanced rare disease 
medical center with the most advanced medical services in China, Southeast Asia 
and other surrounding areas", the center will actively explore successful 
operation models to bridge to future national rare disease medical center. The 
functions of the center include introducing advanced rare disease medicines and 
devices, providing high-end medical services, cooperating with manufacturers, 
insurance companies and other stakeholders to solve affordability issues, 
undertaking real-world studies in the short term, and other clinical trials in 
the future to support registration of overseas rare disease products in China, 
hosting and participating in domestic and oversea academic activities and 
patient group activities to facilitate the improvement of disease awareness and 
the level of diagnosis and treatment for rare diseases.

Forward-looking statements

This announcement contains forward-looking statements, reflecting the current 
beliefs and expectations of Winhealth Pharma Group (HK). These statements are 
based on expectations and assumptions about the current available information 
and are subject to known and unknown risks and uncertainties that may cause 
actual results to differ significantly from such statements. We have no 
willingness or obligation to update or modify any forward-looking statements, 
whether as a result of additional information, future events or other 
circumstances.

SOURCE  Winhealth Pharma Group HK